Results show up before the scale moves.
The first GLP-1 weight loss result most patients notice isn't a number on the scale. It's the food noise going quiet within 3 to 7 days. The scale doesn't move meaningfully until weeks 3 to 4, after the first dose increase, and the dramatic GLP-1 weight loss results land between months 6 and 14. Trial averages: 15% body weight loss on Wegovy (semaglutide), 21% on Zepbound (tirzepatide), 24% on retatrutide in Phase 2.
This page covers what GLP-1 weight loss results actually look like month by month, what the trial data shows, why results vary, and four real before/after photos from users online who shared their journeys.
🔑 Key Takeaways
- GLP-1 weight loss results follow a predictable curve: ~5% body weight at month 1, ~10% at month 3, 15-20% by month 12.
- Tirzepatide outperforms semaglutide in head-to-head data: 20.2% vs 13.7% body weight loss at 72 weeks (SURMOUNT-5, NEJM 2025).
- The first sign isn't weight loss. It's appetite suppression and food noise quieting in days 3 to 7.
- Plateaus at months 4 to 6 are normal and usually resolve at the next dose increase. They don't mean the drug stopped working.
- Real-world GLP-1 weight loss results lag trial averages by 2 to 4 percentage points because adherence drops and titration is slower outside controlled studies.
- Stopping cold reverses GLP-1 weight loss results in most patients (about two-thirds of lost weight returns within 12 months without maintenance).
Real GLP-1 weight loss results from users online
Four real GLP-1 weight loss results photos from users online who publicly shared their journeys. Identifiers blurred for privacy. Click any photo to expand.
Photos sourced from users online who publicly shared their GLP-1 results. All four used compounded semaglutide or tirzepatide, the same medications available through Yucca Health and MEDVi telehealth. Individual GLP-1 weight loss results vary; trial average is 15-20% body weight loss at 60+ weeks.
The trial data behind GLP-1 weight loss results
Every conversation about GLP-1 weight loss results should start with the trials. These are not marketing numbers, they are FDA submission data from registered clinical trials.
| Drug | Trial | Dose | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide (Wegovy) | STEP-1 | 2.4 mg/week | 68 weeks | 14.9% |
| Tirzepatide (Zepbound) | SURMOUNT-1 | 15 mg/week | 72 weeks | 22.5% |
| Tirzepatide vs Semaglutide | SURMOUNT-5 (NEJM 2025) | 15 mg vs 2.4 mg | 72 weeks | 20.2% vs 13.7% |
| Liraglutide (Saxenda) | SCALE | 3.0 mg/day | 56 weeks | ~8% |
| Retatrutide (Phase 2) | TRIUMPH-1 | 12 mg/week | 48 weeks | 24.2% |
Three things to take from this. First, GLP-1 weight loss results scale with mechanism: single-receptor (liraglutide, semaglutide) trails dual-receptor (tirzepatide), which trails triple-receptor (retatrutide). Second, the 15-20% range is real and reproducible across thousands of patients. Third, the longer the trial runs, the closer patients get to peak loss; most plateau between months 12 and 18.
GLP-1 weight loss results month by month
Month 1: appetite drops, scale barely moves
The first GLP-1 weight loss result is psychological. Within 3 to 7 days, food noise quiets. You eat half your usual lunch and feel full. Snacking thoughts that ran on a constant loop go silent. Most patients are still on the starter dose this month (semaglutide 0.25 mg, tirzepatide 2.5 mg), which is sub-therapeutic by design. Average month-1 GLP-1 weight loss result: 3 to 6 lbs.
Months 2 to 3: momentum phase
The dose titrates up at week 4 and again at week 8. This is where the scale starts moving consistently. Most patients lose 1 to 2 lbs per week during months 2 and 3. By the end of month 3, average GLP-1 weight loss results land at 8 to 12% body weight. Visible changes: face leanness ("Ozempic face" is just facial fat loss), clothes fitting differently, waist circumference dropping 2 to 4 inches.
Months 4 to 6: first plateau
Almost every patient hits a 2 to 4 week plateau between month 4 and month 6. This is the most common quit point. It usually resolves at the next dose increase (semaglutide 1.7 to 2.4 mg, tirzepatide 10 to 15 mg). By end of month 6: average GLP-1 weight loss results are 12 to 17% body weight on tirzepatide, 9 to 14% on semaglutide. Side effects typically diminish; the GI cluster fades by month 4 for most patients.
Months 7 to 12: continued grinding
Weight loss slows from 1 to 2 lbs/week to 0.5 to 1 lb/week. Body recomposition continues. Most STEP-1 trial participants hit their personal low between month 12 and 14. By end of month 12, GLP-1 weight loss results stabilize at the per-trial averages: ~15% sema, ~21% tirz. Non-scale victories often outweigh the scale: better sleep, less joint pain, lower BP.
Beyond month 12: maintenance
Once you hit your goal weight, the conversation shifts. Many patients stay on a lower maintenance dose. Some titrate down with their clinician. Stopping cold reliably reverses about two-thirds of GLP-1 weight loss results within 12 months (per STEP-4 extension data). Maintenance dosing keeps the loss with fewer side effects.
Why GLP-1 weight loss results vary patient to patient
Trial averages are bell curves. The 15% Wegovy mean includes patients who lost 5% and patients who lost 25%. Five factors explain most of the variance:
- Dose reached. Most "low responders" are stuck at sub-therapeutic doses because side effects scared them away from titrating up. Reaching the target dose is the single biggest predictor.
- Adherence. Skipping or delaying weekly doses cuts results 20 to 40%. Real-world adherence is 60-70%; trial adherence is 90+%.
- Protein intake. Below 80g/day, you lose more muscle than fat, which lowers RMR and produces a "skinny but not lean" outcome. 100-160g/day preserves muscle and improves body composition.
- Starting weight. Heavier starting weight tends to produce more absolute loss but similar percent loss.
- Drug choice. Tirzepatide produces ~50% more loss than semaglutide at max dose (per SURMOUNT-5).
Real-world vs clinical-trial GLP-1 weight loss results
Real-world GLP-1 weight loss results lag trial averages by 2 to 4 percentage points. Trials use rigorous adherence support; the real world has insurance lapses, supply shortages, and titration pacing issues. Practical numbers our readers report:
- Wegovy real-world result at 12 months: 11 to 14% body weight (vs 15% trial average).
- Zepbound real-world result at 12 months: 16 to 19% body weight (vs 21% trial average).
- Compounded semaglutide via telehealth: similar to Wegovy if titrated to therapeutic dose.
- Compounded tirzepatide via telehealth: similar to Zepbound at matched dose.
What slows GLP-1 weight loss results
- Liquid calories. GLP-1s suppress solid-food appetite but don't blunt liquid calories the same way. Smoothies, juice, and alcohol bypass the satiety mechanism.
- Inadequate protein. Without 100+g/day, you lose lean mass and your BMR drops, which causes plateaus.
- Slow titration. Spending 3+ months on the starter dose means 3 months of minimal loss.
- Stress and sleep deprivation. Cortisol and sleep loss both impair GLP-1 receptor sensitivity.
- Medications that work against you. Some antipsychotics, corticosteroids, and beta-blockers blunt GLP-1 effects.
How to maximize your GLP-1 weight loss results
- Reach the therapeutic dose. Don't park at a starter dose if you can tolerate higher.
- Hit 100-160g protein/day. Whey shakes, Greek yogurt, eggs, lean meats. Eat protein first.
- Resistance train 2-3x/week. Preserves muscle so the loss is fat, not lean tissue.
- Hydrate aggressively. 80-100oz/day. Most "side effects" trace to dehydration on lower food intake.
- Don't quit at the month 4-6 plateau. Titrate up, don't quit. Plateaus resolve.
- Walk 10-15 min after meals. Improves blood sugar response and gut comfort.
- Track waist circumference, not just weight. Body composition is changing under the scale.
How to access the GLP-1 medications behind these results
Three legitimate paths in 2026:
- Brand prescription via insurance. Wegovy or Zepbound, prior auth required, BMI ≥30 (or ≥27 with comorbidity).
- Brand cash via LillyDirect or NovoCare. Zepbound vials $349-$499/mo, Wegovy $499/mo direct from manufacturers.
- Compounded via telehealth. Compounded semaglutide from $146/mo, compounded tirzepatide from $258/mo. Yucca Health and MEDVi are the two providers our readers use most. Both use US-licensed clinicians and US compounding pharmacies.
Frequently Asked Questions
The bottom line on GLP-1 weight loss results
GLP-1 weight loss results are real, predictable, and well-documented. The trial data has held up across hundreds of thousands of patients: 15% on Wegovy, 21% on Zepbound, more on retatrutide. Real-world results lag trials by a few percentage points but produce life-changing loss for the majority who titrate to a therapeutic dose and stay on through the inevitable plateaus.
For deeper context, see our GLP-1 before and after timeline, our best GLP-1 for weight loss ranking, our tirzepatide vs semaglutide comparison, our cheapest GLP-1 cost guide, and our how telehealth GLP-1 works guide.
Medical Disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 weight loss results vary significantly between patients. GLP-1 medications including semaglutide and tirzepatide are prescription drugs that require evaluation by a licensed clinician. Always disclose your full medical history during intake, follow your prescribing clinician's titration schedule, and seek in-person care for severe side effects. Compounded GLP-1 medications are dispensed under FDA 503A and 503B oversight but are not FDA-approved finished products. This article contains affiliate links; we may earn a commission when you order through them.
